Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
12/2005
12/14/2005EP1603392A2 Paclitaxel hybrid derivatives
12/14/2005EP1112255B1 4,4-biarylpiperidine derivatives with opioid receptor activity
12/14/2005CN1708468A Novel compounds, their preparation and use
12/14/2005CN1708293A S1p receptor agonist for treating demyelinate disease
12/14/2005CN1708292A Fast dissolving films for oral administration of drugs
12/14/2005CN1708269A Compositions and methods for transdermal oxybutynin therapy
12/14/2005CN1706814A Ultrafine-l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same
12/14/2005CN1231431C Process for preparing substituted 2-3-dihydro-1-indanones
12/13/2005US6974868 A 6-(7-((2-(phenyl)cyclopropyl)amino)-5-(propylthio)-3H-1,2, 3-triazolo(4,5-d)pyrimidin-3-yl)-tetrahydro-2,2-dimethyl-4H-cyclopentane-1,2-diol derivative; anticoagulants; myocardial infarction, strokes; thrombolytic and antiischemic agents;
12/13/2005US6974815 effective as antagonists of Leukointegrins and/or ICAMs
12/13/2005US6974812 such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders (rheumatoid arthritis)
12/13/2005CA2001328C Borrelia antigen
12/08/2005WO2005115422A2 Compositions containing avocado leaf extract for lowering cholesterol levels
12/08/2005WO2005115304A2 Use of c-kit inhibitors for treating fibrodysplasia
12/08/2005WO2005115303A1 Purification of insulin-like material by reverse phase chromatography
12/08/2005WO2005092039A3 Crosslinked amine polymers
12/08/2005WO2005058239A3 Apparatus and methods for forming and securing gastrointestinal tissue folds
12/08/2005WO2005058234A3 Methods and compositions relating to ccr5 antagonist, ifn-ϝ and il-13 induced inflammation
12/08/2005WO2005055951A3 Methods and compositions for slowing aging
12/08/2005WO2005041882A3 Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
12/08/2005WO2005041881A3 Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
12/08/2005WO2005034873A3 A method for reducing anti-neoplastic agent induced side-effects
12/08/2005WO2005032452A3 Alkyl-substituted pcdf as a treatment for prostate cancer
12/08/2005WO2005030149A3 Suppression of hiv replication for prevention and treatment of hiv
12/08/2005WO2005018555A3 Lipid-modified immune response modifiers
12/08/2005WO2005018534A3 Methods and compositions for rna interference
12/08/2005WO2005011580A3 Compositions and methods for herpes simplex prophylaxis and treatment
12/08/2005WO2005011578A2 Preoperative treatment of post operative pain
12/08/2005WO2005009384A3 Egfr tyrosine kinase inhibitors
12/08/2005WO2005009383A3 Methods of treatment with lxr agonists
12/08/2005WO2004112729A8 Dual function compounds and uses thereof
12/08/2005WO2004096139A8 Aza spiro alkane derivatives as inhibitors of metalloproteases
12/08/2005WO2004096134A3 Substituted 1,4-diazepines and uses thereof
12/08/2005WO2004093805A3 Selective spirocyclic glucocorticoid receptor modulators
12/08/2005WO2004093798A3 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
12/08/2005WO2004082617A3 Biological markers for diagnosing rheumatoid arthritis
12/08/2005WO2004069173A3 Methods for modulating an inflammatory response
12/08/2005WO2004069172A3 Multilineage-inducible cells and uses thereof
12/08/2005WO2004066948A3 Mapcaxs as modifiers of the apc and axin pathways and methods of use
12/08/2005WO2004066912A3 Anti-inflammatory compositions and uses thereof
12/08/2005WO2004056315A8 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
12/08/2005WO2004045522A3 Absolute quantitation of nucleic acids by rt-pcr
12/08/2005US20050272943 Process for preparing prostaglandin derivatives and starting materials for the same
12/08/2005US20050272796 Prevention and treatment of benign prostatic hyperplasia using lonidamine and lonidamine analogs
12/08/2005US20050272795 Prevention and treatment of benign prostatic hyperplasia
12/08/2005US20050272711 Substance for lowering high cholesterol level in serum and methods for preparing and using the same
12/08/2005US20050272697 Composition and method for treating post-surgical pain
12/08/2005US20050272686 Nucleotide based medicament and method of use for treatment of conditions in humans
12/08/2005US20050272029 Hepatitis c viral-like particle purification
12/08/2005US20050271723 Dosage forms for treatment of benign prostatic hyperplasia
12/08/2005US20050271689 Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
12/08/2005US20050271631 Material compositions and related systems and methods for treating cardiac conditions
12/08/2005US20050271604 Matrix protein compositions for wound healing
12/07/2005EP1601965A2 Animal model simulating neurologic disease
12/07/2005EP1601789A2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
12/07/2005EP1601678A2 Fused pyrrole compounds
12/07/2005EP1601652A2 Pyridinium salts, compounds and methods of use
12/07/2005EP1601374A2 Compositions and methods for diagnosing and treating an inflammation
12/07/2005EP1601372A2 Clk-peptide and slk-peptide
12/07/2005EP1601370A2 Rapidly absorbing lipophilic skin compositions and uses therefor
12/07/2005EP1601368A2 Methods and compositions for treatment of viral diseases
12/07/2005EP1601367A2 The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
12/07/2005EP1601348A2 Compositions and methods with enhanced therapeutic activity
12/07/2005EP1601339A2 Skin peeling composition and method
12/07/2005EP1601334A2 Aerosol antiperspirant with polyamide
12/07/2005EP1601333A2 Novel insertion sites in pox vectors
12/07/2005EP1601332A2 Hydrolases, nucleic acids encoding them and mehods for making and using them
12/07/2005EP1601330A2 Antitumor agents comprising a targeting portion and an immune response triggering portion
12/07/2005EP1601329A2 Automated insomnia treatment system
12/07/2005EP1601328A2 Polyvalent immunogen
12/07/2005EP1601326A2 Random alkylene oxide copolymers for medical and surgical utilities
12/07/2005EP1601251A2 Compounds for the treatment of metabolic disorders
12/07/2005EP1156802B1 Pharmaceutic, dietetic and cosmetic compositions based on thioctic acid and cysteine
12/07/2005CN1705740A Adenovirus expressing genes in reverse order and use thereof
12/07/2005CN1705662A Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
12/07/2005CN1705647A Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/07/2005CN1704423A Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
12/07/2005CN1230539C Bacterial auto-inducer inactivation protein, its coded nucleic acid molecule and uses
12/07/2005CN1230170C Remedies or preventives for pulmonary insufficiency containing diaminotrifluoromethylpyridine derivatives
12/07/2005CN1230159C Essential fatty acids in prevention of cardiovascular events
12/06/2005US6972175 Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods
12/06/2005CA2303537C Solid oral dosage form comprising a combination of metformin and glibenclamide
12/01/2005WO2005113763A1 Inhibition of erk-phosphorylation
12/01/2005WO2005051330B1 METHOD FOR TREATING HUMAN TUMOR CELLS WITH A NEWCASTLE DISEASE VIRUS STRAIN HAVING A p53 INDEPENDENT ONCOLYTIC EFFECT
12/01/2005WO2005048950A3 Tumor and infectious disease therapeutic compositions
12/01/2005WO2005048933A3 Oxime substituted imidazo ring compounds
12/01/2005WO2005041868A3 Epidermal growth factor receptor modulation protects normal tissue
12/01/2005WO2005037195A3 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
12/01/2005WO2005032491A3 Methods and compositions for mycoplasma pneumoniae exotoxins
12/01/2005WO2005025487A3 Oligonucleotides targeting prion diseases
12/01/2005WO2005023196A3 Compounds and methods
12/01/2005WO2005013895A3 Compositions and methods for the treatment of schizophrenia and addictive disorders
12/01/2005WO2005007124A3 Substituted dihydropyrimidine inhibitors of calcium channel function
12/01/2005WO2005007071A3 Skin formulation
12/01/2005WO2004096118B1 Composition for improving cognition and memory
12/01/2005WO2004082629A3 Novel cyclosporins
12/01/2005WO2004075845A3 Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
12/01/2005WO2004071384A3 New pharmaceutical compositions based on anticholinergics and tace-inhibitors
12/01/2005WO2004064775A3 Sigma-2 receptor agonists and their use in the treatment of hiv infection
12/01/2005WO2003049703A8 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
1 ... 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 ... 295